SCHEMBL4281847

SCHEMBL4281847

Cc1cc(Nc2nccc(-c3ccc(NC(=O)C(C)(C)C)cc3)n2)ccc1N1CC2CCC(C1)N2C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 9/20 0.45
▸ BRD4 O60885 1/20 0.44
▸ CDK9 P50750 1/20 0.44
▸ EGFR P00533 1/20 0.43
▸ SYK P43405 1/20 0.43
▸ JAK3 P52333 4/20 0.43
▸ CDK2 P24941 4/20 0.43
▸ CCNA2 P20248 2/20 0.43
▸ CCNA1 P78396 2/20 0.43
▸ MTOR P42345 3/20 0.43
▸ CDK1 P06493 2/20 0.42
▸ PIK3CA P42336 2/20 0.42
▸ PIK3CG P48736 2/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15391058 0.87 JAK2 (0.44) JAK2BRD4CDK9EGFRSYK
SCHEMBL4279960 0.84 JAK2 (0.43) JAK2BRD4CDK9JAK3CDK2
SCHEMBL4287781 0.84 JAK2 (0.43) JAK2BRD4CDK9JAK3CDK2
SCHEMBL4284345 0.79 JAK2 (0.47) JAK2BRD4CDK9EGFRJAK3
SCHEMBL4277766 0.78 ZAP70 (0.59) JAK2EGFRJAK3CDK2MTOR
SCHEMBL4281844 0.77 JAK2 (0.41) JAK2JAK3CDK2MTORCDK1
SCHEMBL4277994 0.77 JAK2 (0.41) JAK2JAK3CDK2MTORCDK1
SCHEMBL4277867 0.77 JAK2 (0.46) JAK2JAK3CDK2CCNA2CCNA1
SCHEMBL4285347 0.77 JAK2 (0.46) JAK2JAK3CDK2CCNA2CCNA1
SCHEMBL4279895 0.77 JAK2 (0.72) JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624229-B2 Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases RIGEL PHARMACEUTICALS, INC. (US) 2017-04-18 — — US disclosed
EP-2265607-B1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS INC (US) 2016-12-14 — — EP disclosed
US-20140213585-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2014-07-31 — — US disclosed
US-8735418-B2 Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases RIGEL PHARMACEUTICALS, INC. (US) 2014-05-27 — — US disclosed
US-20130018041-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICAL, INC. (US) 2013-01-17 — — US disclosed
US-8309566-B2 Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases RIGEL PHARMACEUTICALS, INC. (US) 2012-11-13 — — US disclosed
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2009-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213585-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 JAK2 1/4885BRD4 251/4885CDK9 59/4885
US-20130018041-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 JAK2 1/4885BRD4 468/4885CDK9 15/4885
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 JAK2 1/4885BRD4 535/4885CDK9 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback